Sutro Biopharma, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Net Loss Per Share (Tables)

Net Loss Per Share (Tables)

6 Months Ended

Jun. 30, 2019

Summary of Computation of Company's Basic and Diluted Net Loss per Share

The following table sets forth the computation of the Company’s basic and diluted net loss per share.

	Three Months Ended June 30,						Six Months Ended June 30,
	2019			2018			2019			2018
Numerator:
Net loss, basic and diluted	$	(13,793	)	$	(11,541	)	$	(28,043	)	$	(23,587	)
Net loss	$	(13,793	)	$	(11,541	)	$	(28,043	)	$	(23,587	)
Denominator:
Shares issued in computing net loss per share, basic and diluted		22,926,390			477,521			22,895,902			472,647
Net loss per share, basic and diluted	$	(0.60	)	$	(24.17	)	$	(1.22	)	$	(49.90	)

Summary of Common Stock Equivalents of Antidilutive Securities Excluded from Computation of Diluted Net Loss per Share

The following common stock equivalents were excluded from the computation of diluted net loss per share for the periods ended June 30, 2019 and 2018, because including them would have been antidilutive:

	As of June 30,
	2019		2018
Redeemable convertible preferred stock		–		9,259,852
Common stock options and restricted stock awards issued and outstanding		4,361,843		820,875
Warrants to purchase redeemable convertible preferred stock		–		114,876
Warrants to purchase common stock		71,813		1,099
Total		4,433,656		10,196,702